German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition

BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering

Plus: Chipscreen to commercialize Eucure’s bispecific in China and updates from Reata, SpringWorks

SpringWorks also taps investor syndicate for $225M private placement, extending runway into 2026 as submission looms in desmoid tumors

Despite PFS benefit in clinical study for desmoid tumors, safety concerns suggest use of nirogacestat could be limited

Buysiders view 2021 as a window of opportunity for investing in targeted cancer drugs

Global biopharma IPOs have raised $4.4B across 19 offerings so far this year